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Resolvins are generated from omega-3 fatty acids during inflammatory responses in the
lung. These natural mediators interact with specific receptors to decrease lung inflamma-
tion and promote its resolution in healthy tissues.There are several lung diseases of chronic
inflammation that fail to resolve, most notable asthma.This common disorder has a lifetime
prevalence of nearly 10% and is characterized, in part, by chronic, non-resolving inflamma-
tion of the airway. Pro-resolving mediators are generated during asthma; however, their
biosynthesis is decreased in severe and uncontrolled asthma, suggesting that the chronic,
adaptive inflammation in asthmatic airways may result from a resolution defect.This article
focuses on recent insights into the cellular and molecular mechanisms for resolvins that
limit adaptive immune responses in healthy airways.
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INTRODUCTION
The recent identification of specialized mediators that promote
tissue resolution from acute inflammation and injury has opened
a new window for discovery of cellular and molecular mechanisms
governing chronic inflammation and adaptive immunity. Chronic
“unresolved” inflammation is a pathologic response that is associ-
ated with several common human diseases for which there is no
cure. Asthma is an exemplary illness with chronic inflammation
that has a lifetime prevalence of nearly 1 in 10 in Western countries
(Fanta, 2009). The chronic inflammation in asthma consists of air-
way infiltration of eosinophils and T-lymphocytes with increased
levels of pro-phlogistic cytokines and lipid mediators (Busse and
Lemanske, 2001). Of interest, many patients with uncontrolled
Abbreviations: ALX/FPR2, lipoxin A4 receptor/formyl peptide receptor
2; AT-RvD1, aspirin-triggered-resolvin D1 (7S,8R,17R-trihydroxy-docosa-
4Z,9E,11E,13Z,15E,19Z -hexaenoic acid); AT-RvD2, aspirin-triggered-resolvin
D2 (7S,16R,17R-trihydroxy-docosa-4Z,8E,10Z,12E,14E,19Z -hexaenoic acid);
AT-RvD3, aspirin-triggered-resolvin D3 (4S,11R,17R-trihydroxy-docosa-
5,7E,9E,13Z,15E,19Z -hexaenoic acid); AT-RvD4, aspirin-triggered-resolvin
D4 (4S,5R,17R-trihydroxy-docosa-6E,8E,10Z,13Z,15E,19Z -hexaenoic acid);
BALF, bronchoalveolar lavage fluid; BLT1, LTB4 receptor; CMKLR1,
chemokine receptor-like 1; DHA, docosahexaenoic acid; EPA, eicosapentaenoic
acid; LC-UV-MS/MS, liquid chromatography-ultraviolet spectrometry-
tandem mass spectrometry; LOX, lipoxygenase; LTB4, leukotriene B4
(5S,12R-dihydroxy-eicosa-6Z,8E,10E,14Z -tetraenoic acid); LXA4, lipoxin
A4 (5S,6R,15S-trihydroxy-eicosa-7E,9E,11Z,13E-tetraenoic acid); PD1, pro-
tectin D1 (10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z -hexaenoic
acid); RvD1, resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z -
docosahexaenoic acid); RvD2, resolvin D2 (7S,16R,17S-trihydroxy-docosa-
4Z,8E,10Z,12E,14E,19Z -hexaenoic acid); RvD3, resolvin D3 (4S,11,17S-
trihydroxy-5E,7E,9E,13Z,15E,19Z -docosahexaenoic acid); RvD4, resolvin D4
(4S,5,17S-trihydroxy-6E,8E,10Z,13Z,15E,19Z -docosahexaenoic acid); RvE1,
resolvin E1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid);
RvE2, resolvin E2 (5S,18R-dihydroxy-8Z,11Z,14Z,16E-eicosapentaenoic acid; SAA,
serum amyloid A; TGF-β, transforming growth factor-beta.
lung inflammation, including clinically severe asthma, display a
defect in the generation of specialized pro-resolving mediators
(Levy et al., 2005, 2007; Planaguma et al., 2008; Table 1), consistent
with a failure to establish sufficient protective counter-regulatory
pathways in the asthmatic lung.
Catabasis is a healthy host tissue response to noxious stim-
uli. The literal definition of catabasis refers to a military retreat
and the term has been adopted for use to describe the resolution
process of returning an inflamed or injured tissue to homeostasis
after the “battle” of inflammation. Catabasis requires well orches-
trated cellular responses in which soluble mediators appear to play
critical roles (Serhan, 2007). For resolution (Majno, 1996), restitu-
tion of endothelial and epithelial cell barrier integrity is necessary
to prevent continued edema formation. Additional granulocyte
recruitment is blocked and those granulocytes that have infil-
trated the tissue undergo programmed cell death. The apoptotic
cells are then cleared, principally by macrophages. The phago-
cytes also clear tissue microbes and debris, and structural cells
re-establish organ function. One family of mediators for these
pro-resolving cellular actions is the resolvins, which are enzymat-
ically derived from the omega-3 fatty acids eicosapentaenoic acid
(i.e., E-series resolvins) and docosahexaenoic acid (i.e., D-series
resolvins; Serhan et al., 2000, 2002). Together with the lipoxins,
protectins, and maresins, the resolvins comprise a new genus of
endogenous, specialized pro-resolving mediators (Serhan, 2007).
These mediators serve as agonists at select receptors to trans-
duce their cell type specific pro-resolving actions (Serhan, 2007).
Defects in resolvin signaling pathways can be resolution “toxic”
in model systems, leading to conversion of acute inflammatory
responses to more chronic pathologic inflammation (Schwab et al.,
2007), supporting a potential link for defective resolvin signaling
to chronic inflammatory diseases. Of interest, there appears to be
population heterogeneity in resolution mechanisms. Randomly
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Table 1 | Uncontrolled lung inflammation – A defect in specialized pro-resolving mediators.
Pro-resolving mediator Disease Finding Reference
Lipoxin A4 Aspirin-exacerbated
respiratory disease
Aspirin-tolerant asthmatics generate more
lipoxins than aspirin-intolerant asthmatics
Sanak et al. (2000), Celik et al. (2007),
Yamaguchi et al. (2011)
Severe asthma Diminished lipoxin biosynthesis in severe
asthma
Levy et al. (2005), Vachier et al. (2005),
Celik et al. (2007), Planaguma et al.
(2008), Bhavsar et al. (2010), Wu et al.
(2010), Fritscher et al. (2012)
Bronchoconstriction in
asthma
Protects against bronchoprovocation by either
LTC4 or exercise
Tahan et al. (2008), Christie et al. (1992)
Asthma exacerbation Decreased lipoxin levels in exhaled breath
during exacerbation
Hasan et al. (2012)
Cystic fibrosis Decreased generation and actions in cystic
fibrosis
Karp et al. (2004), Yang et al. (2012),
Chiron et al. (2008), Mattoscio et al. (2010)
Scleroderma lung disease Decreased lipoxin levels in BALFs Kowal-Bielecka et al. (2005)
Resolvin E1 Cystic fibrosis Decreased resolvin E1 levels in cystic fibrosis
with a relationship to lung function
Yang et al. (2012)
Protectin D1 Asthma exacerbation Decreased Protectin D1 in uncontrolled asthma Levy et al. (2007)
selected healthy individuals display significant differences in the
pace of resolution for acute exudative inflammation with segre-
gation of these apparently healthy subjects into discrete cohorts
of rapid and delayed resolvers (Morris et al., 2010) that may
be partially explained by genetic variability, which has recently
been linked to inflammatory disease (Simiele et al., 2011). In
health, the conversion of acute to chronic airway inflammation
is prevented by endogenous pro-resolving mechanisms for tissue
catabasis.
Intrinsically linked to innate immune responses, the develop-
ment of adaptive immunity is essential to host defense, but unreg-
ulated adaptive inflammation can also lead to disease, including
autoimmune disorders, transplant rejection, and allergy. As part
of a series of review articles exploring the research theme of “Res-
olution of inflammation: leukocytes and molecular pathways as
potential therapeutic targets,” this article will focus on the regula-
tion of adaptive inflammatory responses by resolvins, in particular
shared and distinct counter-regulatory mechanisms for resolvin E1
and resolvin D1 in allergic inflammation.
RESOLVINS AND THEIR RECEPTORS IN THE LUNG
Eicosapentaenoic acid is an essential fatty acid that can be enzy-
matically converted to E-series resolvins, including resolvin E1,
resolvin E2, and resolvin E3, during inflammation in mammals
and fish (Serhan et al., 2000; Isobe et al., 2012). These media-
tors display stereoselective and cell type specific actions. Resolvin
E1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic
acid) can transduce its biological actions by interacting with spe-
cific G-protein coupled receptors, namely chemokine-like receptor
1 (CMKLR1) and leukotriene B4 receptor 1 (BLT1; Arita et al.,
2005a, 2007). RvE1 serves as an agonist for CMKLR1, which is
expressed in macrophages, dendritic cells (DCs), natural killer
(NK) cells, and other T cells, and RvE1 serves as a receptor
antagonist at BLT1 for leukotriene B4. BLT1 is expressed on granu-
locytes, T cells, and macrophages. Resolvin E1 and resolvin E2 (5S,
18R-dihydroxy-6E,8Z,11Z,14Z,16E-eicosapentaenoic acid) are
generated via the actions of 5-lipoxygenase (ALOX5) from
a common precursor 18-hydroxyeicosapentaenoic acid (18-
HEPE) with two parallel stereospecific pathways (Arita et al.,
2005a; Tjonahen et al., 2006; Oh et al., 2012). Resolvin
E3 [17,18(R/S)-dihydroxy-5Z,8Z,11Z,13E,15E-eicosapentaenoic
acid] is distinct from RvE1 and RvE2 because it is generated
via the actions of 12/15-lipoxygenase (ALOX12/15; Isobe et al.,
2012). Since ALOX5 and ALOX12/15 are generally compart-
mentalized into distinct leukocyte classes, neutrophils (ALOX5)
appear to play significant roles in RvE1 and RvE2 genera-
tion, while eosinophils (ALOX12/15) are significant in RvE3
biosynthesis.
Docosahexaenoic acid is another essential omega-3 fatty
acid that can be enzymatically converted to resolvins. In a
lipoxygenase-dependent manner, DHA is transformed to D-
series resolvins, including resolvin D1–D6, during inflamma-
tion (Serhan, 2007). These mediators also display stereoselec-
tive and cell type specific actions. Resolvin D1 (7S,8R,17S-
trihydroxy-4Z,9E,11E,13Z,15E,19Z -docosahexaenoic acid) trans-
duces its biological actions by interacting with specific G-protein
coupled receptors, including the lipoxin A4 receptor ALX/FPR2
and, in humans, GPR32 (Sun et al., 2007; Krishnamoorthy
et al., 2010, 2012). RvD1 serves as an agonist for both of these
receptors. ALX/FPR2 is broadly expressed in many cells types,
including most leukocytes as well as structural cells, such as air-
way epithelial cells (Chiang et al., 2006). GPR32 is expressed
on phagocytes (Krishnamoorthy et al., 2010). There are also
aspirin-triggered 17R D-series resolvins (AT-RvD1–4) that are
generated in human and murine tissues, including lung, and
AT-RvD1 can also interact with ALX/FPR2 and GPR32 recep-
tors (Krishnamoorthy et al., 2012). Of note, in an aspirin-
independent manner, cytochrome P450 enzymes, which are
abundant in the lung, can also convert DHA to 17R-hydroxy-
DHA that can serve as a precursor for 17R-RvD1 (i.e., AT-
RvD1), so the presence of aspirin is not required for AT-RvD1
generation.
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Relatively little information is currently available on most of
these recently identified E-series and D-series resolvins regarding
their actions during lung inflammation; however, recent evidence
has identified important roles for resolvin E1 and resolvin D1 and
their cellular targets in promoting the resolution of lung inflam-
mation (Aoki et al., 2008; Haworth et al., 2008, 2011; Seki et al.,
2010; Bilal et al., 2011; Wang et al., 2011; Eickmeier et al., 2012; El
Kebir et al., 2012; Rogerio et al., 2012), including allergic airway
responses (Aoki et al., 2008; Haworth et al., 2008, 2011; Bilal et al.,
2011; Rogerio et al., 2012).
EXPRESSION OF CMKLR1 – CELL TYPE, LUNG TISSUE,
ASTHMA
CMKLR1 is highly expressed in immature plasmacytoid DCs and
at lower levels in myeloid DCs, macrophages, and NK cells (Arita
et al., 2005a; Parolini et al., 2007). The CMKLR1 signaling path-
way is structurally and functionally conserved between human
and mouse. In a model of zymosan induced peritonitis, CMKLR1
deficient mice, exhibit increased inflammation, indicating that this
receptor is important for counter-regulatory signaling (Cash et al.,
2008). Both RvE1 and chemerin can interact with CMKLR1 and
display potent anti-inflammatory properties in LPS-induced acute
lung inflammation in mice, reducing neutrophil infiltration and
inflammatory cytokine release in a CMKLR1-dependent manner
(Luangsay et al., 2009).
The expression of CMKLR1 in plasmacytoid DCs suggests
an important role in anti-viral immunity. When wild-type and
CMKLR1 knock-out mice are infected by pneumonia virus of
mice, the CMKLR1 deficient mice display higher mortality and
morbidity, alteration of lung function, delayed viral clearance and
increased neutrophilic infiltration. The CMKLR1 deficient mice
have a lower recruitment of plasmacytoid DCs and a reduction
in type I interferon production. Recruitment of plasmacytoid
DCs via CMKLR1 contributes to adaptive immune responses and
viral clearance, but also enhances the inflammatory response.
Anti-inflammatory pathways involving CMKLR1 expressed by
non-leukocytic cells in the lung also contribute to the increased
morbidity/mortality in CMKLR1 deficient mice (Bondue et al.,
2011).
Of interest, CMKLR1 signaling in acute lung inflammation
appears context dependent. In a separate model of acute lung
inflammation, cigarette smoke-induced lung inflammation was
attenuated in CMKLR1 deficient mice with decreased levels of
inflammatory chemokines and inflammatory cells. In addition,
the infiltration of leukocytes persists for 14 days after cessation of
smoke exposure in this model in wild-type mice, but the CMKLR1
deficient mice have a marked decrease in lung T cells at this time
point (Demoor et al., 2011). Together, these findings indicate that
the RvE1 receptor CMKLR1 is expressed in the lung by both leuko-
cytes and structural cells and CMLKR1 signaling plays pivotal roles
in the regulation of innate and adaptive immune cell activation in
the lung.
The recruitment of CMKLR1-expressing leukocytes to the
lung is regulated during inflammatory responses. Following acute
LPS-induced lung inflammation, NK cells expressing CMKLR1
are recruited to the airways in a CCRL2-dependent manner.
Engagement of CCRL2 on endothelial cells initiates adhesion
of CMKLR1-expressing lymphoid cells through an α(4)β(1)
integrin/VCAM-1-dependent mechanism. CCRL2 expression by
endothelial cells is regulated by cell activation, so CMKLR1-
dependent lymphocyte adhesion to endothelial cells can be tar-
geted to sites of inflammation, including inflamed lung (Monnier
et al., 2012).
EXPRESSION OF ALX/FPR2 – CELL TYPE, LUNG TISSUE,
ASTHMA
ALX/FPR2 is expressed in several types of leukocytes (Chiang
et al., 2006), including neutrophils (Fiore et al., 1992, 1994), mono-
cytes (Maddox and Serhan, 1996), eosinophils (Levy et al., 2002),
myeloid progenitors (Stenke et al., 1991), NK cells (Ramstedt
et al., 1987; Haworth et al., 2011), and activated T cells (Ariel
et al., 2003), as well as resident cells such as macrophages (God-
son et al., 2000), synovial fibroblasts (Sodin-Semrl et al., 2000),
and intestinal epithelial cells (Gronert et al., 1998). ALX/FPR2 is
expressed in murine and human lung (Planaguma et al., 2008;
Rogerio et al., 2012), airway epithelial cells (Bonnans et al., 2003,
2006), and alveolar macrophages (Rogerio et al., 2012). As early
as 2 h after acute lung injury or inflammation, ALX/FPR2 expres-
sion increases in mucosal epithelial cells (Bonnans et al., 2006).
Counter-regulatory signaling via ALX/FPR2 has been demon-
strated in vivo using ALX/FPR2 deficient mice (Dufton et al., 2010)
and transgenic mice that express human ALX/FPR2 directed by a
component of the myeloid CD11b promoter (Devchand et al.,
2003). ALX/FPR2 deficient mice have more marked inflamma-
tory responses with increased leukocyte adherence and emigration
into inflamed tissue after ischemia-reperfusion injury and after
carrageenan-induced paw edema. In addition, ALX/FPR2 knock-
out mice display increased sensitivity to arthrogenic serum and
fail to resolve from this chronic inflammatory arthritis (Dufton
et al., 2010). Also of note, human ALX/FPR2-transgenic mice
have decreased inflammatory responses and are protected from
the development of allergic airway inflammation with markedly
decreased eosinophil activation and tissue accumulation (Levy
et al., 2002). In asthma, ALX/FPR2 receptor expression is regulated
in a cell type specific manner with decreases in peripheral blood
neutrophil and eosinophil expression in this chronic inflammatory
condition (Planaguma et al., 2008).
Recently, in subjects with chronic obstructive pulmonary dis-
ease, serum amyloid A (SAA) was identified as a biomarker for
acute exacerbations (Bozinovski et al., 2008). SAA can also inter-
act with ALX/FPR2 receptors, and unlike RvD1 or LXA4, the
SAA-ALX/FPR2 interactions are pro-inflammatory (Bozinovski
et al., 2012). Because plasma levels of SAA are at least two-log
orders higher than LXA4 during acute exacerbations (Bozinovski
et al., 2012), the pro-inflammatory SAA-ALX/FPR2 signaling can
overwhelm the pro-resolving mediator protective signaling at this
receptor. The balance of ALX/FPR2 ligands during asthma and the
influence of corticosteroids is a subject of on-going investigation.
ALLERGIC AIRWAY RESPONSES – AN EXPERIMENTAL
MODEL OF ADAPTIVE IMMUNITY AND ASTHMA
Animal models have not been developed that fully resemble
human asthma, but they are quite useful for investigation of
adaptive immunity and asthma traits. To model allergic airway
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inflammation, animals are first sensitized to an allergen and then
challenged by respiratory tract exposure to the same allergen
(Kips et al., 2003; Corry and Irvin, 2006; Pichavant et al., 2007;
Zosky and Sly, 2007). Roles for representative family members
of D-series resolvins and E-series resolvins have been determined
using a model in which chicken ovalbumin (OVA) serves as an
allergen for in-bred mice. The animals are sensitized by intraperi-
toneal injection of OVA combined with the adjuvant aluminum
hydroxide to initiate a strong Th2 phenotype (Aoki et al., 2008;
Haworth et al., 2008, 2011; Bilal et al., 2011; Rogerio et al., 2012).
In sensitized mice, OVA aerosol challenge on four consecutive
days leads to adaptive inflammation consisting of predominantly
eosinophils and T-lymphocytes, in particular in medium to small
airways and alveoli (Levy, 2010). There is also perivascular inflam-
mation. Antigen-induced responses also increase airway mucus
metaplasia and hyper-responsiveness (Levy, 2010). To determine
the extent of the airway hyper-responsiveness, methacholine is
administered via inhalation while the mice are intubated and
sedated on a ventilator circuit. A dose response curve is constructed
for methacholine-initiated changes in lung resistance.
In most instances, the airway inflammation of asthma in
humans does not resolve completely; however, in healthy airways,
inhalation of potential allergens or provocative stimuli leads to an
acute inflammatory response that is self-limited. Several classes
of natural anti-inflammatory mediators, including resolvins, have
been identified in inflamed airways (Bilal et al., 2011; Eickmeier
et al., 2012). Because the clinical presentation of asthma is after the
disease has already developed, more recent research has focused
on the natural factors that promote resolution of allergic air-
way responses and identification of potential disease mechanisms
that counter these endogenous, protective signals to perpetuate
inflammation and potentially maladaptive airway responses. In
the murine model of allergic airway responses described above,
the cessation of OVA aerosol challenge leads to self-limited lung
inflammation with resolution of the adaptive immune responses
within 1–2 weeks (Haworth et al., 2008). Investigation of the res-
olution phase of allergic airway responses has uncovered several
pro-resolving molecular and cellular mechanisms for adaptive air-
way inflammation (Levy et al., 2007; Haworth et al., 2008, 2011;
Rogerio et al., 2012). NK cells were recently assigned important
roles for clearance of antigen-specific T cells. During the nat-
ural resolution phase of allergic airway inflammation, eosinophils,
and T cells decrease markedly concomitant with an increase in
the numbers of NK cells in the lung and associated mediasti-
nal lymph nodes (Haworth et al., 2011). These resolution NK
cells also acquire cell surface markers, including NKG2D, consis-
tent with NK cell activation (Haworth et al., 2011). The timely
resolution of allergic airway inflammation is prolonged when
NK cells are depleted, blocked from interacting with target cells,
or inhibited from migrating to the lung, leading to a persis-
tence of airway eosinophils and antigen-specific CD4 (Haworth
et al., 2011) T cells (Haworth et al., 2011). Lung macrophages
also serve important pro-resolving roles in the clearance of aller-
gic airway inflammation. After the respiratory tract is exposed
to allergen, lung macrophages display a significant capacity for
clearance of airway antigen that was introduced during aerosol
challenge (Rogerio et al., 2012). These recent findings identify
important pro-resolving roles for innate lung tissue lympho-
cytes and macrophages in the regulation of adaptive immune
responses.
ACTIONS OF RvD1 AND RvE1 IN ALLERGIC AIRWAY
INFLAMMATION
LC-MS/MS-based lipido-metabolomic analyses of inflamed
murine lung reveals picogram quantities of RvD1 and RvE1 that
can be increased several fold with increased substrate availabil-
ity (Bilal et al., 2011; Eickmeier et al., 2012). In asthma, airway
mucosal epithelial cells have depleted stores of docosahexaenoic
acid (Freedman et al., 2004) and lower levels of 17-hydroxy-DHA
and protectin D1 in exhaled breath condensates compared with
healthy control subjects (Levy et al., 2007). Recently, the potential
beneficial actions of resolvins in experimental models of airway
mucosal inflammation have been reported.
Lung expression of the RvD1 receptor ALX/FPR2 is induced
in vivo in allergic airway inflammation (Levy et al., 2002). When
RvD1 is given to OVA-sensitized mice just prior to OVA aerosol
challenge, the development of allergic airway responses is sig-
nificantly decreased (Rogerio et al., 2012). In particular, RvD1
markedly decreases eosinophils and levels of IL-4, IL-5, and IL-13
in bronchoalveolar lavage fluids (BALFs), consistent with a dom-
inant effect of the mediator on the development of Th2 adaptive
inflammation. Regulation of these cytokines by RvD1 is associated
with a significant increase in lung IκBα, suggesting decreased acti-
vation of NF-κB. Airway mucus metaplasia is also decreased by
RvD1 with a more modest effect on airway hyper-responsiveness
to methacholine. BALF levels of the counter-regulatory mediators
IL-10 and LXA4 are not increased by RvD1 administration, indi-
cating non-redundant anti-inflammatory signaling circuits for
these mediators.
Potent regulation by RvD1 and AT-RvD1 of the allergen-driven
accumulation of eosinophils was linked to significant decrements
in BALF IL-5, eotaxin, and LTB4 (Rogerio et al., 2012). In many
asthmatics, a Th2 cytokine gene expression signature is induced
(Woodruff et al., 2007), including IL-5, which is an important
cytokine for the recruitment and activation of eosinophils, espe-
cially in conjunction with eotaxins (Busse and Lemanske, 2001).
IL-5, eotaxin, NF-κB activation (Yang et al., 1998), and LTB4 (Ter-
awaki et al., 2005) can all increase airway eosinophilia. In murine
allergic airway inflammation, RvD1 and AT-RvD1 decreased each
of these mediators of eosinophil activation and accumulation.
Eosinophils may also play important roles in airway remod-
eling and can generate the pro-fibrotic growth factor TGF-β1
(Wong et al., 1991). The RvD1 and AT-RvD1 mediated decrease in
eosinophils and TGF-β levels (Rogerio et al., 2012) suggest addi-
tional beneficial actions for these mediators in preventing chronic
airway remodeling. Further study in models of chronic inflamma-
tion is needed to address this potential tissue protective role for
these D-series resolvins.
When administered after acute airway inflammation is estab-
lished, RvD1 significantly and rapidly decreases the allergic lung
inflammation within 1 h (Rogerio et al., 2012). Because RvD1
is subject to rapid inactivation in the lung, it is impact is tran-
sient (Rogerio et al., 2012), so when RvD1 is given daily for three
consecutive days, there is only a modest decrease in the BALF
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eosinophil resolution interval over the subsequent week (Rogerio
et al., 2012). Of note, an equivalent dose and administration of AT-
RvD1 (∼0.005 mg/kg) provides significantly greater pro-resolving
actions than RvD1, including a marked decrease in the BALF
eosinophil resolution interval by more than 50% – an approxi-
mate doubling of the pace of resolution! Both of these D-series
resolvins are agonists at ALX/FPR2 receptors albeit with differ-
ent binding kinetics (Perretti et al., 2002; Krishnamoorthy et al.,
2010, 2012; Norling et al., 2012). In addition, the metabolism of
these epimers is distinct (Sun et al., 2007). In the presence of lung
macrophages, AT-RvD1 has a decreased rate of metabolic inacti-
vation relative to RvD1 (Rogerio et al., 2012). RvD1 and AT-RvD1
are diastereomers, differing only in stereochemistry at carbon 17
(reviewed in Serhan et al., 2008). This change in stereochem-
istry for AT-RvD1 provides a significant increase in the mediator’s
half-life in vivo, secondary to resistance to metabolic inactivation
by eicosanoid oxidoreductases (Sun et al., 2007; Krishnamoorthy
et al., 2012).
AT-RvD1 displays potent pro-resolving actions on molecular
and cellular inflammatory responses. During resolution of aller-
gic airway responses, BALF levels of IL-17, eotaxin, TARC, TGF-β,
and LTB4 are significantly decreased by AT-RvD1 administration
(Rogerio et al., 2012). For tissue catabasis after antigen challenge, it
is essential to clear the allergen from the lung. Lung macrophages
play critical roles in this catabatic process (Thornton et al.,
2012). AT-RvD1 increases the macrophage phagocytosis index for
OVA in vitro and in vivo (Rogerio et al., 2012). By promoting
more rapid allergen clearance by lung macrophages, AT-RvD1
accelerates the pace of resolution of allergic airway responses,
namely adaptive airway inflammation, mucus metaplasia, and
hyper-responsiveness to methacholine.
Resolvin E1 is also a potent anti-inflammatory and pro-
resolving mediator for allergic airway responses. Similar to RvD1,
RvE1 can prevent the development allergic airway responses in
this murine model of asthma (Levy et al., 2002, 2007; Haworth
et al., 2008). When RvE1 is administered intravenously, it potently
inhibits the induction of allergic airway inflammation (Aoki
et al., 2008; Haworth et al., 2008) and when given during the
resolution phase of inflammation, RvE1 accelerates the clear-
ance of airway inflammation, mucus metaplasia, and hyper-
reactivity to methacholine (Haworth et al., 2008, 2011). These
RvE1-mediated bronchoprotective actions during resolution are
multi-pronged, including inhibition of Th17 effector lympho-
cytes, engagement of activated NK cells and increased generation
of interferon-gamma (IFN-γ) and LXA4 (Haworth et al., 2008,
2011). After cessation of allergen exposure, the timely resolu-
tion of allergic airway responses is governed by regulation of
the Th17 pathway (Haworth et al., 2008). This is in sharp con-
trast to the pivotal roles for Th2 cytokines during the devel-
opment of allergic lung inflammation (vide supra). IL-17 can
be generated by several cell types in asthmatic lung, including
Th17 cells that are a subset of CD4+ T helper cells character-
ized by the production of IL-17 and whose population expansion
and survival depends upon IL-23. IL-17 has been linked to the
pathogenesis of many inflammatory diseases, is present in the
airways of asthmatic patients and can induce lung inflamma-
tion, airway hyper-reactivity and mucus production (Chen et al.,
2003; Haworth et al., 2008; Al-Ramli et al., 2009; Alcorn et al.,
2010; Lajoie et al., 2010). Similar to RvD1 and AT-RvD1, RvE1
also regulates IL-17 to promote resolution of allergic airways
responses.
Identification of an important role for IL-17 in the persis-
tence of lung inflammation, in particular during allergic airway
inflammation, is supported by several lines of evidence. Trans-
genic expression of IL-17 in airway epithelial cells induces airway
eosinophil and lymphocyte infiltration and structural changes
with mucus metaplasia (Park et al., 2005). Mice deficient for
the IL-17 receptor are protected from allergen-induced airway
inflammation (Schnyder-Candrian et al., 2006), and in humans,
asthmatic subjects have higher levels of BALF and sputum IL-
17 (Molet et al., 2001; Barczyk et al., 2003; Schnyder-Candrian
et al., 2006). Indicative of its importance in the lung, IL-17 may
have dual roles in the regulation of allergic airway inflammation,
as it can also inhibit TH2 immune responses in model systems
(Schnyder-Candrian et al., 2006). In promoting resolution, RvE1
significantly decreases both IL-17 and allergic airway responses
(Haworth et al., 2008), supporting a relationship between IL-17
and persistent airway inflammation.
In addition to IL-17, BALF levels of IL-23 are also decreased by
administration of RvE1. IL-23 is also involved in the pathobiology
of chronic inflammatory diseases, including colitis, encephalitis,
psoriasis, rheumatoid arthritis, and cancer (Langrish et al., 2005;
Chan et al., 2006; Langowski et al., 2006; Yago et al., 2007), and
IL-23 is critical for the survival of TH17 cells (Langrish et al., 2005;
Bettelli et al., 2006). IL-23 induces the release of pro-inflammatory
chemokines from eosinophils, which express the IL-23 receptor
(Cheung et al., 2008). Moreover, IL-23 deficient mice are protected
in models of chronic inflammation, such as colitis (Yen et al., 2006).
Of note, RvE1 also protects against the development of colitis in
model systems (Arita et al., 2005b; Hudert et al., 2006). Thus, regu-
lation of IL-23 by RvE1 appears critical to its pro-resolving actions
in mucosal inflammation.
As mentioned above, NK cells express the RvE1 receptor
CMKLR1 (Arita et al., 2005a; Parolini et al., 2007). NK cell deple-
tion impairs RvE1’s protective actions for the timely resolution
of adaptive inflammation (Haworth et al., 2011). RvE1 regulates
NK cell homing, increases clearance of antigen-specific CD4+
T cells and increases NK cell cytotoxicity. Circulating and lung
NK cell numbers increase with RvE1 administration, consistent
with a role for RvE1 in NK cell transit through the inflamed lung
to its associated mediastinal lymph nodes. RvE1 induces CXCL9
expression in the lung and mediastinal lymph nodes. Antibody-
mediated inhibition of CXCL9-CXCR3 interactions blocks NK cell
infiltration into inflamed lung and lymph nodes, and delays res-
olution of adaptive airway inflammation. These findings indicate
that RvE1 can regulate tissue chemokines to target NK cell homing
to the lung for catabasis. The influence of D-series resolvins and
ALX/FPR2 signaling on NK cell functional responses is an area of
active investigation.
Current anti-inflammatory therapeutic strategies for asthma
include corticosteroids, CysLT1 receptor antagonists and anti-
IgE antibody (Fanta, 2009). While little is known regarding
the influence of these approaches on the actions of resolvins,
their independent signaling pathways suggest that the resolvins
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would complement existing therapeutics. Corticosteroids share
the resolvins’ anti-inflammatory actions on eosinophils and T
cells; however, they do not share resolvins’ pro-resolving actions
for macrophages and NK cells. CysLT1 receptor antagonists
and anti-IgE antibody target specific pro-phlogistic pathways
and would not be expected to interfere with the resolvins’
mechanisms of action. Regarding pharmacological considera-
tions for the resolvins, these mediators carry potent actions
in sub-nanomolar concentrations in vitro (reviewed in Serhan,
2007) and at doses of ∼0.005 mg/kg in vivo (Haworth et al.,
2008; Rogerio et al., 2012). As with the Fat-1 transgenic mouse
(Bilal et al., 2011), increasing the tissue levels of omega-3 fatty
acids can increase resolvin formation and offer protection from
allergic airway responses; however, dietary supplementation is
less potent than direct administration of resolvins (Seki et al.,
2010).
SHARED AND DISTINCT PRO-RESOLVING MECHANISMS FOR
RvE1 AND RvD1/AT-RvD1 IN ADAPTIVE INFLAMMATION
RvE1 and RvD1/AT-RvD1 are agonists at distinct pro-resolving
receptors, yet share many similar properties in the regulation of
adaptive inflammation in the lung (Figure 1, Table 2). These
mediators decrease recruitment of lung eosinophils, lymphocytes,
and macrophages during adaptive immune responses and decrease
allergic airway responses, including mucus metaplasia and hyper-
responsiveness to methacholine. In addition, these specialized
pro-resolving mediators share many similarities in the regula-
tion of lung inflammatory peptide and lipid mediators. Despite
these commonalities, the RvE1 and RvD1/AT-RvD1 pro-resolving
pathways are not entirely redundant. In addition to their distinct
Table 2 | Shared and distinct pro-resolving mechanisms for RvE1 and
RvD1/AT-RvD1 during murine adaptive inflammation.
Receptors RvE1 RvD1/AT-RvD1 LXA4 analog
CMKLR1 BLT1 ALX/FPR2 ALX/FPR2 CysLT1
ALLERGIC AIRWAY RESPONSES
Inflammation
Eosinophils Decreased Decreased Decreased
Lymphocytes Decreased Decreased Decreased
NK Cells Increased
Macrophages Decreased Increased
Mucus metaplasia Decreased Decreased Decreased
MCh ED200 Increased Increased Increased
CYTOKINES
IL-4 No change No change
IL-5 No change Decreased
IL-6 Decreased
IL-10 No change No change
IL-13 No change No change
IL-17 Decreased Decreased Decreased
IL-23 Decreased Decreased No change
IL-27 Decreased
Interferon-gamma Increased No change Decreased
CHEMOKINES
Eotaxin Decreased
TARC Decreased
LIPID MEDIATORS
LTB4 Decreased Decreased
CysLTs No change
LXA4 Increased No change
FIGURE 1 | Cellular targets for resolvins in allergic inflammation.
Shared and distinct anti-phlogistic and pro-resolving actions are
illustrated for RvD1 (D1) and RvE1 (E1). These natural mediators have
independent signaling pathways initiated via interactions with distinct
receptors, yet they share many overlapping properties at the cellular
and tissue levels.
Frontiers in Immunology | Inflammation December 2012 | Volume 3 | Article 390 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levy Resolvins in allergic airway inflammation
receptors, there are clear differences between RvE1 and RvD1/AT-
RvD1 in the regulation of BALF levels of IL-5, IFN-γ, and LXA4
during resolution (Haworth et al., 2008, 2011; Rogerio et al., 2012).
While there is no data on concomitant administration of RvE1 and
RvD1 in this model, co-administration of RvE1 and a bioactive
LXA4 stable analog, which, like RvD1/AT-RvD1, interacts with
ALX/FPR2 receptors, provides additive pro-resolving actions, yet
there are important differences in their mechanisms. Both RvE1
and the LXA4 analog decrease BALF levels of IL-17, but distinct
from RvE1, the LXA4 analog does not inhibit IL-23 production
or increase IFN-γ levels (Haworth et al., 2008). These findings of
shared and distinct points of counter-regulation for RvE1 and
the LXA4 stable analog indicate the presence of independent
pro-resolving signaling circuits, likely mediated by CMKLR1 and
ALX/FPR2 respectively, which in this model of adaptive immu-
nity converge on the regulation of IL-17 to promote catabasis
(Table 2). Of interest, when administered during the upstroke
of allergic inflammation, both RvD1 and RvE1 are also potent
regulators of the development of airway hyper-responsiveness to
methacholine, mucus metaplasia, eosinophil accumulation, and
TH2 cytokine mediator release (e.g., IL-13; Haworth et al., 2008,
2011). Regulation of IL-13 by resolvins during induction of adap-
tive inflammation is distinct from their actions when given during
resolution. When given after the adaptive inflammation is already
established, these resolvins do not lead to significant changes in
BALF levels of IL-13; however, both RvD1 and RvE1 lead to
marked decreases in BALF levels of IL-17. While the mecha-
nisms that induce adaptive inflammation (i.e., TH2 cytokines)
are distinct from those linked to persistent mucosal inflamma-
tion (i.e., IL-17 and IL-23), the protective actions of resolvins
include regulation of both of these important families of inflam-
matory mediators. Inhibition of IL-17 production appears to be
a common point of regulation for RvE1 and RvD1 for resolution
of allergic airway responses (Serhan et al., 2000; Haworth et al.,
2011).
SUMMARY AND CONCLUSIONS
The recent discovery of resolvins, endogenously gener-
ated from the essential fatty acids docosahexaenoic acid
and eicosapentaenoic acid, has uncovered molecular and
cellular mechanisms for the resolution of acute and adaptive
inflammation. These specialized and stereospecific pro-resolving
chemical mediators play important roles in limiting allergic air-
way responses and promoting catabasis of the inflamed lung. In the
lung, resolvins are enzymatically generated during cell–cell inter-
actions, often between leukocytes and structural cells. Their inter-
actions with specific receptors establish resolution circuits with
cell type specific functional responses. While RvD1 and RvE1 share
some cellular targets and pro-resolving actions, there is accumu-
lating evidence for distinct counter-regulatory signaling pathways,
including distinct receptors. In response to acute inflammation,
these endogenous mediators blunt the inflammatory response by
inhibiting aberrant neutrophil trafficking and activation, stimu-
lating efferocytosis of apoptotic neutrophils and promoting anti-
angiogenic, anti-fibrotic, and anti-infective actions. In allergic
immune responses, resolvins enlist NK cells to facilitate clearance
of activated T cells and activate macrophages (in a non-phlogistic
manner) for phagocytic removal of allergen deposited in inflamed
lung. Rapidly formed during inflammatory responses, these auta-
coids are also rapidly inactivated by eicosanoid oxidoreductases.
In the setting of chronic inflammatory lung disease, airway levels
of omega-3 fatty acids and pro-resolving mediators are decreased.
With no curative therapy currently available for asthma or sev-
eral other chronic inflammatory diseases, the development of
resolvin stable analogs is leading to exciting new potential ther-
apeutic approaches in acute and adaptive chronic inflammation
that emphasize these natural homeostatic pathways.
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